ALK and non-small cell lung carcinoma: Despite the efficacy of second-generation ALK TKIs, patients with ALK-positive NSCLC progressing on these agents often present with a high incidence of CNS metastases, ranging from 40–84% in addition to difficult-to-treat ALK resistant mutations [6,7,8,9,10,11,12,13].